A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer.

Bibliographic Details
Title:	A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer.
Authors:	Girda, Eugenia¹ (AUTHOR), Makker, Vicky² (AUTHOR), Marth, Christian³ (AUTHOR), Van Gorp, Toon⁴ (AUTHOR), Mirza, Mansoor⁵ (AUTHOR), Shapira-Frommer, Ronnie⁶ (AUTHOR), Suttner, Leah⁷ (AUTHOR), Groisberg, Roman⁷ (AUTHOR), Jin, Fan⁷ (AUTHOR), O'Malley, David⁸ (AUTHOR)
Source:	Gynecologic Oncology. 2024 Supplement 1, Vol. 190, pS293-S294. 2p.
Subject Terms:	ENDOMETRIAL cancer, PEMBROLIZUMAB
Database:	Academic Search Complete